Based on these findings, we designed and identified a dual-targeting compound, LZFPN-90, targeting PD-L1 may improve the tumor’s immune microenvironment, and targeting NAMPT can inhibit cell growth, block the cell cycle, and subsequently induce apoptosis. Here, NAMPT is linked to neoplasm.